Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

In my opinion, combination therapy is here to stay, and has its own niche in the treatment of symptomatic BPH. CLICK HERE for subscription information about this journal.

WASHINGTON — Only 8% of patients with pulmonary arterial hypertension initiating combination therapy were given both medications on the same day, according to research presented at the American ...

Triple combination therapy shows promise for COVID-19 patients with less severe illnesses The trio of drugs include ribavirin, lopinavir-ritonavir and Interferon beta 1b.